CD44 and integrin α2β1 were described as CSC markers based on studies of prostate cancer samples [9] and several prostate cancer cell lines [12,45], but not PC3 cells, where both markers were found on 100% of the cells [3,12]. This evidence concerns the gene CD44 and prostate carcinoma.